We are live on ! Find out more
KDNY

Chinook Therapeutics, Inc. Common Stock
KDNY

Delisted

KDNY was delisted on the 10th of August, 2023.

Back to rankings

2 hedge funds and large institutions have $0 invested in Chinook Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 181 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 185 → 2 (-183)

100% less funds holding in top 10

Funds holding in top 10: 10 → 0 (-10)

100% less capital invested

Capital invested by funds: $2.24B → $0 (-$2.24B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 181

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
-183
Holders Change %
-98.92%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
-10
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
181
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SB
Samsara BioCapital
California
-$198M
2
FLSM
Frazier Life Sciences Management
California
-$167M
3
BlackRock
BlackRock
New York
-$164M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$113M
5
State Street
State Street
Massachusetts
-$112M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
– -$198M -5,161,888 Closed
FLSM
2
Frazier Life Sciences Management
California
– -$167M -4,345,559 Closed
BlackRock
3
BlackRock
New York
– -$164M -4,263,241 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$113M -2,948,165 Closed
State Street
5
State Street
Massachusetts
– -$112M -2,907,317 Closed
AAM
6
Alpine Associates Management
Florida
– -$81.9M -2,131,000 Closed
EAM
7
Eventide Asset Management
Massachusetts
– -$74M -1,927,000 Closed
SCM
8
Suvretta Capital Management
New York
– -$67.2M -1,748,141 Closed
FCM
9
Farallon Capital Management
California
– -$58.5M -1,523,000 Closed
BBA
10
Baker Bros. Advisors
New York
– -$55.9M -1,455,202 Closed
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
– -$51.4M -1,336,934 Closed
Franklin Resources
12
Franklin Resources
California
– -$49.7M -1,294,656 Closed
MF
13
Magnetar Financial
Illinois
– -$48.5M -1,262,060 Closed
Federated Hermes
14
Federated Hermes
Pennsylvania
– -$47.4M -1,232,546 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$40.7M -1,060,417 Closed
MB
16
MPM BioImpact
Massachusetts
– -$38.6M -1,003,406 Closed
VC
17
Vivo Capital
California
– -$35.9M -934,879 Closed
NIP
18
Nicholas Investment Partners
California
– -$35.7M -928,637 Closed
TAL
19
TIG Advisors LLC
New York
– -$34.3M -893,435 Closed
CS
20
Candriam SCA
Luxembourg
– -$31.7M -826,155 Closed
LCM
21
Laurion Capital Management
New York
– -$31.7M -824,380 Closed
AllianceBernstein
22
AllianceBernstein
Tennessee
– -$31M -808,046 Closed
N
23
Nuveen
North Carolina
– -$26M -675,828 Closed
WP
24
Woodline Partners
California
– -$23.7M -617,907 Closed
Balyasny Asset Management
25
Balyasny Asset Management
Illinois
– -$23.3M -605,294 Closed
1
2 3 4 5

KDNY Hedge Fund Activity: Q3 2023 in Review

2 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q3 2023, worth a combined $0 — down 100% from $2.24B a quarter earlier.

Sellers outnumbered buyers: 181 funds closed out of KDNY and 0 opened new positions — a net loss of 181 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Samsara BioCapital, exiting entirely with an estimated $198M sold.

  • 2 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q3 2023, down from 185 in Q2 2023.
  • Funds reported $0 of Chinook Therapeutics, Inc. Common Stock stock for Q3 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q3 2023 and 181 closed out, a net change of -181 holders.
  • The largest Chinook Therapeutics, Inc. Common Stock seller in Q3 2023 was Samsara BioCapital, an estimated $198M sold.

Based on aggregated 13F filings for Q3 2023.